DeepMed Research

SANTEN, INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public, Subsidiary

Established: 1993-01-01

Employees: 1K

Market Cap: -

Website: http://www.santeninc.com

Clinical Trials

Study Assessing the Efficacy and Safety of STN1013600 Ophthalmic Solution 0.1% and 0.3% Compared With Placebo in Subjects With Presbyopia

Phase 2

Completed

Conditions: Presbyopia

Interventions: Drug: 0.1% STN1013600 ophthalmic solution
Drug: 0.3% STN1013600 ophthalmic solution
Drug: Placebo

First Posted Date: 2022-12-27

Last Posted Date: 2024-05-29

Lead Sponsor: Santen Inc.

Target Recruit Count: 79

Registration Number: NCT05665387

Locations: 🇺🇸
Eye Research Foundation, Newport Beach, California, United States
🇺🇸
Asheville Eye Associates, Asheville, North Carolina, United States
🇺🇸
R and R Eye Research LLC, San Antonio, Texas, United States

and more 9 locations

A Multicenter Study Assessing the Efficacy and Safety of STN1010904 Ophthalmic Suspension 0.03% and 0.1% Compared With Vehicle in Subjects With Fuchs Endothelial Corneal Dystrophy (FECD)

Phase 2

Active, not recruiting

Conditions: Fuchs Endothelial Corneal Dystrophy

Interventions: Drug: STN1010904 ophthalmic suspension 0.1% BID
Drug: Placebo (Vehicle) BID
Drug: STN1010904 ophthalmic suspension 0.03% BID

First Posted Date: 2022-05-17

Last Posted Date: 2024-05-14

Lead Sponsor: Santen Inc.

Target Recruit Count: 80

Registration Number: NCT05376176

Locations: 🇺🇸
Scott Christie and Associates, Cranberry Township, Pennsylvania, United States
🇫🇷
University Hospital of Saint-Etienne, Saint-Étienne, France
🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States

and more 12 locations

Multicenter Study Assessing the Efficacy and Safety of DE-126 Ophthalmic Solution 0.002% Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension

Phase 2

Completed

Conditions: Ocular Hypertension
Primary Open Angle Glaucoma

Interventions: Drug: DE-126 Ophthalmic Solution 0.002% QD
Drug: Timolol Maleate Ophthalmic Solution 0.5% BID

First Posted Date: 2021-02-08

Last Posted Date: 2023-06-22

Lead Sponsor: Santen Inc.

Target Recruit Count: 323

Registration Number: NCT04742283

Locations: 🇺🇸
Vance Thompson Vision - ND, W. Fargo, North Dakota, United States
🇺🇸
Northern New Jersey Eye Institute, South Orange, New Jersey, United States
🇺🇸
Black Hills Regional Eye Institute, Rapid City, South Dakota, United States

and more 38 locations

Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution Once Daily and Twice Daily in Subjects With Primary Open-Angle Glaucoma SPECTRUM 6

Phase 2

Completed

Conditions: Primary Open-angle Glaucoma and Ocular Hypertension

Interventions: Drug: DE-117 Ophthalmic Solution QD
Drug: DE-117 Ophthalmic Solution BID

First Posted Date: 2019-03-01

Last Posted Date: 2020-08-04

Lead Sponsor: Santen Inc.

Target Recruit Count: 98

Registration Number: NCT03858894

Locations: 🇺🇸
Levenson Eye Associates, Jacksonville, Florida, United States
🇺🇸
Tekwani Vision Center, Saint Louis, Missouri, United States
🇺🇸
Eye Associates/SurgiCenter of Vineland, Vineland, New Jersey, United States

and more 10 locations

LUMINA Phase III Study Assessing the Efficacy and Safety of Intravitreal Injections of 440 ug DE-109 Sirolimus for the Treatment of Active, Non-Infectious Uveitis of the Posterior Segment of the Eye

Phase 3

Terminated

Conditions: Non Infectious Uveitis

Interventions: Drug: DE-109 Intravitreal Injections (Open Label)
Drug: DE-109 Intravitreal Injections
Other: Sham Procedure

First Posted Date: 2018-10-19

Last Posted Date: 2023-12-04

Lead Sponsor: Santen Inc.

Target Recruit Count: 145

Registration Number: NCT03711929

Locations: 🇺🇸
Kaiser Permanente Medical Center, Los Angeles, California, United States
🇺🇸
Emory Eye Center, Atlanta, Georgia, United States
🇺🇸
Cumberland Valley Retina Consultants, Hagerstown, Maryland, United States

and more 62 locations

DE-117 Spectrum 5 Study

Phase 3

Completed

Conditions: Primary Open-angle Glaucoma and Ocular Hypertension

Interventions: Drug: DE-117 Ophthalmic Solution

First Posted Date: 2018-10-05

Last Posted Date: 2023-08-30

Lead Sponsor: Santen Inc.

Target Recruit Count: 107

Registration Number: NCT03697811

Locations: 🇺🇸
Asheville Eye Associates, PLLC, Asheville, North Carolina, United States
🇺🇸
Shettle Eye Research, Inc., Largo, Florida, United States
🇺🇸
Glaucoma Consultants and Center for Eye Research, PA, Mount Pleasant, South Carolina, United States

and more 29 locations

A Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 4 Study

Phase 3

Completed

Conditions: Glaucoma and Ocular Hypertension

Interventions: Drug: Timolol Maleate Ophthalmic Solution 0.5%
Drug: DE-117 Ophthalmic Solution

First Posted Date: 2018-10-02

Last Posted Date: 2023-08-09

Lead Sponsor: Santen Inc.

Target Recruit Count: 417

Registration Number: NCT03691662

Locations: 🇺🇸
North Bay Eye Associates Inc., Petaluma, California, United States
🇺🇸
East Florida Eye Institute, Stuart, Florida, United States
🇺🇸
Vistar Eye Center, Roanoke, Virginia, United States

and more 30 locations

A Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 3 Study

Phase 3

Completed

Conditions: Glaucoma and Ocular Hypertension

Interventions: Drug: Timolol Maleate Ophthalmic Solution 0.5%
Drug: DE-117 Ophthalmic Solution

First Posted Date: 2018-10-02

Last Posted Date: 2023-08-30

Lead Sponsor: Santen Inc.

Target Recruit Count: 426

Registration Number: NCT03691649

Locations: 🇺🇸
Heart of America Eye Care, P.A., Shawnee Mission, Kansas, United States
🇺🇸
Eye Associates of Fort Myers, Fort Myers, Florida, United States
🇺🇸
Shettle Eye Research, Largo, Florida, United States

and more 44 locations

A Phase IIb Safety and Efficacy Study of DE-126 Ophthalmic Solution in Primary Open-Angle Glaucoma or Ocular Hypertension- Angel Study

Phase 2

Completed

Conditions: Open-angle Glaucoma, Ocular Hypertension

Interventions: Drug: Vehicle of DE-126 Ophthalmic Solution, high dose of DE-126 Ophthalmic Solution
Drug: Topical ultra-low dose of DE-126 Ophthalmic Solution
Drug: Topical low dose of DE-126 Ophthalmic Solution
Drug: Topical medium dose of DE-126 Ophthalmic Solution
Drug: Topical high dose of DE-126 Ophthalmic Solution
Drug: 0.005% Latanoprost Ophthalmic Solution

First Posted Date: 2017-07-13

Last Posted Date: 2020-10-23

Lead Sponsor: Santen Inc.

Target Recruit Count: 241

Registration Number: NCT03216902

Locations: 🇺🇸
Cornerstone Health Care, LLC, High Point, North Carolina, United States
🇺🇸
Coastal Research Associates, LLC, Roswell, Georgia, United States
🇯🇵
Sapporo Katoh Ophthalmology Clinic, Sapporo-shi, Hokkaido, Japan

and more 14 locations

Study Assessing the Efficacy and Safety of Intravitreal Injections of DE-122 in Combination With Lucentis® Compared to Lucentis® Monotherapy in Wet Age-related Macular Degeneration Subjects

Phase 2

Completed

Conditions: Age-Related Macular Degeneration

Interventions: Drug: 2.0 mg DE-122 Injectable Solution + Lucentis
Drug: Lucentis
Drug: 4.0 mg DE-122 Injectable Solution + Lucentis

First Posted Date: 2017-07-07

Last Posted Date: 2021-07-13

Lead Sponsor: Santen Inc.

Target Recruit Count: 76

Registration Number: NCT03211234

Locations: 🇺🇸
Retina Research Institute, Gilbert, Arizona, United States
🇺🇸
Northern California Retina Vitreous Associates, Mountain View, California, United States
🇺🇸
Retina-Vitreous Associates, Beverly Hills, California, United States

and more 11 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy